Overview

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Status:
Approved for marketing
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Lenvatinib